arcutis
biotherapeutics
presents
new
positive
data
phase
studies
topical
roflumilast
cream
chronic
plaque
psoriasis
atopic
dermatitis
phase
study
patients
plaque
psoriasis
roflumilast
cream
demonstrated
rapid
clinically
significant
reduction
severity
burden
itch
sleep
loss
well
rapid
improvement
symptom
burden
phase
study
atopic
dermatitis
underscores
potential
roflumilast
cream
treatment
common
condition
roflumilast
cream
safe
psoriasis
atopic
dermatitis
patients
phase
studies
highlighting
differentiated
tolerability
profile
company
highlights
study
results
presentations
european
academy
dermatology
venereology
virtual
congress
society
dermatology
physician
assistants
digital
conference
virtual
fall
clinical
dermatology
conference
westlake
village
globe
newswire
arcutis
biotherapeutics
nasdaq
arqt
biopharmaceutical
company
focused
developing
commercializing
treatments
unmet
needs
dermatological
diseases
conditions
today
reported
new
positive
data
previously
announced
phase
studies
topical
roflumilast
cream
patients
chronic
plaque
psoriasis
atopic
dermatitis
data
presented
european
academy
dermatology
venereology
eadv
virtual
congress
eadv
virtual
society
dermatology
physician
assistants
spda
digital
conference
virtual
fall
clinical
dermatology
conference
roflumilast
cream
potent
inhibitor
investigated
topical
treatment
chronic
plaque
psoriasis
atopic
dermatitis
two
virtual
presentations
arcutis
shared
data
phase
study
efficacy
roflumilast
cream
itch
highly
prevalent
frequently
bothersome
symptom
chronic
plaque
psoriasis
improving
burden
typical
plaque
psoriasis
symptoms
third
presentation
arcutis
highlighted
results
phase
study
safety
efficacy
roflumilast
cream
patients
atopic
dermatitis
results
phase
studies
highlight
potential
roflumilast
cream
topical
inhibitor
chronic
plaque
psoriasis
atopic
dermatitis
said
patrick
burnett
faad
arcutis
chief
medical
officer
phase
psoriasis
study
data
provide
clinical
evidence
roflumilast
cream
ability
reduce
burden
itch
improve
typical
symptoms
patients
plaque
psoriasis
addition
encouraging
efficacy
results
safety
profile
phase
roflumilast
cream
atopic
dermatitis
provide
solid
foundation
upcoming
pivotal
phase
results
phase
study
plaque
psoriasis
phase
study
patients
randomized
roflumilast
roflumilast
vehicle
baseline
patients
score
investigator
global
assessment
iga
scale
modified
psoriasis
area
severity
index
primary
endpoint
achievement
clear
almost
clear
skin
based
iga
week
itch
assessed
baseline
throughout
trial
using
various
outcome
measures
including
itch
severity
sleep
loss
study
showed
treatment
roflumilast
cream
resulted
rapid
clinically
significant
reduction
severity
burden
itch
compared
vehicle
roflumilast
group
significant
itch
reduction
occurred
week
compared
vehicle
continued
week
patients
achieving
clinically
meaningful
itch
reduction
reduction
itch
also
resulted
significant
improvement
sleep
loss
week
continued
week
phase
study
also
assessed
efficacy
roflumilast
cream
improving
burden
signs
symptoms
plaque
psoriasis
including
stinging
burning
skin
cracking
pain
scaling
doses
roflumilast
cream
led
rapid
robust
improvements
symptom
burden
quality
life
patient
population
study
results
showed
statistically
significant
improvements
roflumilast
doses
compared
vehicle
seen
burden
individual
signs
symptoms
scaling
week
stinging
skin
cracking
pain
week
burning
week
reported
improvements
individual
signs
symptoms
maintained
week
mean
decrease
baseline
overall
patient
symptom
diary
psd
score
roflumilast
groups
respectively
roflumilast
cream
patients
phase
study
rate
application
site
pain
low
similar
vehicle
adverse
events
mild
moderate
results
phase
study
atopic
dermatitis
phase
study
atopic
dermatitis
ad
patients
randomized
roflumilast
roflumilast
vehicle
weeks
patients
body
surface
area
bsa
affected
ad
validated
investigator
global
assessment
ad
score
mild
moderate
eczema
area
severity
index
easi
score
primary
efficacy
endpoint
absolute
change
baseline
easi
score
week
study
results
showed
roflumilast
cream
demonstrated
efficacy
compared
vehicle
ad
although
primary
endpoint
proof
concept
study
showed
trend
towards
reach
statistical
significance
statistical
significance
efficacy
endpoints
reached
statistically
significant
improvements
compared
vehicle
observed
week
including
easi
improvement
patients
achieving
clear
almost
clear
skin
roflumilast
cream
roflumilast
cream
well
tolerated
low
rate
application
site
reactions
local
irritation
virtual
presentations
arcutis
phase
phase
studies
roflumilast
cream
given
eadv
virtual
congress
october
fall
clinical
dermatology
conference
spda
digital
october
november
available
viewing
using
links
scientific
publications
arcutis
website
roflumilast
cream
improved
itch
severity
sleep
loss
adults
chronic
plaque
psoriasis
phase
study
eadv
virtual
congress
fall
clinical
spda
digital
roflumilast
cream
improved
symptom
burden
adults
chronic
plaque
psoriasis
phase
study
eadv
virtual
congress
fall
clinical
spda
digital
safety
efficacy
roflumilast
cream
atopic
dermatitis
phase
study
eadv
virtual
congress
fall
clinical
spda
digital
atopic
dermatitis
atopic
dermatitis
ad
common
type
eczema
occurring
approximately
six
percent
population
ad
characterized
defect
skin
barrier
allows
allergens
irritants
enter
skin
leading
immune
reaction
inflammation
reaction
produces
red
itchy
rash
frequently
occurring
face
arms
legs
rash
cover
significant
areas
body
cases
half
body
disease
onset
common
years
age
company
estimates
approximately
patients
suffering
ad
pediatric
patients
rash
causes
significant
pruritus
itching
lead
skin
damage
caused
scratching
rubbing
given
patients
pediatric
safety
tolerability
ad
therapies
paramount
psoriasis
psoriasis
common
skin
disease
affects
approximately
million
patients
united
states
patients
develop
plaque
psoriasis
characterized
raised
red
areas
skin
covered
silver
white
layer
scale
psoriatic
plaques
appear
area
body
often
appear
scalp
knees
elbows
trunk
limbs
often
itchy
sometimes
painful
plaques
certain
anatomical
areas
present
particular
treatment
challenges
including
face
elbows
knees
scalp
intertriginous
regions
groin
axillae
inframammary
areas
arcutis
bioscience
applied
skin
arcutis
biotherapeutics
nasdaq
arqt
biopharmaceutical
company
focused
developing
commercializing
treatments
unmet
needs
dermatological
diseases
conditions
company
leveraging
recent
advances
immunology
inflammation
develop
differentiated
therapies
biologically
validated
targets
solve
persistent
treatment
challenges
serious
diseases
skin
arcutis
robust
pipeline
includes
four
novel
drug
candidates
currently
development
range
inflammatory
dermatological
conditions
company
lead
product
candidate
topical
roflumilast
potential
revitalize
standard
care
plaque
psoriasis
atopic
dermatitis
scalp
psoriasis
seborrheic
dermatitis
information
visit
follow
company
linkedin
twitter
forward
looking
statements
press
release
contains
statements
including
among
others
statements
regarding
potential
inhibitor
potential
treatment
atopic
dermatitis
potential
treatment
plaque
psoriasis
whether
positive
results
phase
studies
indicative
potential
outcomes
future
studies
statements
involve
substantial
known
unknown
risks
uncertainties
factors
may
cause
actual
results
levels
activity
performance
achievements
materially
different
information
expressed
implied
statements
place
undue
reliance
statements
risks
uncertainties
may
cause
actual
results
differ
include
risks
inherent
clinical
development
process
regulatory
approval
process
timing
regulatory
filings
ability
defend
intellectual
property
description
risks
uncertainties
applicable
business
see
risk
factors
section
form
filed
securities
exchange
commission
sec
august
well
subsequent
filings
sec
undertake
obligation
revise
update
information
herein
reflect
events
circumstances
future
even
new
information
becomes
available
investors
media
heather
rowe
armstrong
vice
president
investor
relations
corporate
communications
harmstrong
ext
